Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer

Detalles Bibliográficos
Autores principales: Yamaguchi, Teppei, Hida, Toyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798102/
https://www.ncbi.nlm.nih.gov/pubmed/35117056
http://dx.doi.org/10.21037/tcr.2019.12.57
_version_ 1784641717253701632
author Yamaguchi, Teppei
Hida, Toyoaki
author_facet Yamaguchi, Teppei
Hida, Toyoaki
author_sort Yamaguchi, Teppei
collection PubMed
description
format Online
Article
Text
id pubmed-8798102
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87981022022-02-02 Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer Yamaguchi, Teppei Hida, Toyoaki Transl Cancer Res Editorial Commentary AME Publishing Company 2019-12 /pmc/articles/PMC8798102/ /pubmed/35117056 http://dx.doi.org/10.21037/tcr.2019.12.57 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Editorial Commentary
Yamaguchi, Teppei
Hida, Toyoaki
Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer
title Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer
title_full Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer
title_fullStr Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer
title_full_unstemmed Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer
title_short Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer
title_sort addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798102/
https://www.ncbi.nlm.nih.gov/pubmed/35117056
http://dx.doi.org/10.21037/tcr.2019.12.57
work_keys_str_mv AT yamaguchiteppei additionofatezolizumabtonabpaclitaxelpluscarboplatinisanewstandardoptionforthefirstlinetreatmentfornonsquamousnonsmallcelllungcancer
AT hidatoyoaki additionofatezolizumabtonabpaclitaxelpluscarboplatinisanewstandardoptionforthefirstlinetreatmentfornonsquamousnonsmallcelllungcancer

Ejemplares similares